These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. Ibañez D; Urowitz MB; Gladman DD J Rheumatol; 2003 Sep; 30(9):1977-82. PubMed ID: 12966601 [TBL] [Abstract][Full Text] [Related]
3. Summarizing disease features over time: II. Variability measures of SLEDAI-2K. Ibañez D; Gladman D; Urowitz M J Rheumatol; 2007 Feb; 34(2):336-40. PubMed ID: 17183620 [TBL] [Abstract][Full Text] [Related]
4. The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. Uribe AG; Vilá LM; McGwin G; Sanchez ML; Reveille JD; Alarcón GS J Rheumatol; 2004 Oct; 31(10):1934-40. PubMed ID: 15468356 [TBL] [Abstract][Full Text] [Related]
6. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. Ibañez D; Gladman DD; Urowitz MB J Rheumatol; 2005 May; 32(5):824-7. PubMed ID: 15868616 [TBL] [Abstract][Full Text] [Related]
7. Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity. Cook RJ; Gladman DD; Pericak D; Urowitz MB J Rheumatol; 2000 Aug; 27(8):1892-5. PubMed ID: 10955329 [TBL] [Abstract][Full Text] [Related]
8. The effect of menopause on disease activity in systemic lupus erythematosus. Urowitz MB; Ibañez D; Jerome D; Gladman DD J Rheumatol; 2006 Nov; 33(11):2192-8. PubMed ID: 16981295 [TBL] [Abstract][Full Text] [Related]
9. SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation. Touma Z; Urowitz MB; Ibañez D; Gladman DD Lupus; 2011 Jan; 20(1):67-70. PubMed ID: 21233149 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. Ward MM; Marx AS; Barry NN J Rheumatol; 2000 Mar; 27(3):664-70. PubMed ID: 10743805 [TBL] [Abstract][Full Text] [Related]
11. Role of specialty care in the management of patients with systemic lupus erythematosus. Urowitz MB; Kagal A; Rahman P; Gladman DD J Rheumatol; 2002 Jun; 29(6):1207-10. PubMed ID: 12064836 [TBL] [Abstract][Full Text] [Related]
12. Serum albumin as a marker for disease activity in patients with systemic lupus erythematosus. Yip J; Aghdassi E; Su J; Lou W; Reich H; Bargman J; Scholey J; Gladman DD; Urowitz MB; Fortin PR J Rheumatol; 2010 Aug; 37(8):1667-72. PubMed ID: 20516026 [TBL] [Abstract][Full Text] [Related]
14. Patterns of disease activity in systemic lupus erythematosus. Barr SG; Zonana-Nacach A; Magder LS; Petri M Arthritis Rheum; 1999 Dec; 42(12):2682-8. PubMed ID: 10616018 [TBL] [Abstract][Full Text] [Related]
15. Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality. Becker-Merok A; Nossent HC J Rheumatol; 2006 Aug; 33(8):1570-7. PubMed ID: 16845708 [TBL] [Abstract][Full Text] [Related]
16. Systemic lupus erythematosus disease activity Index 2000 Responder Index 50: sensitivity to response at 6 and 12 months. Touma Z; Urowitz MB; Taghavi-Zadeh S; Ibañez D; Gladman DD Rheumatology (Oxford); 2012 Oct; 51(10):1814-9. PubMed ID: 22718868 [TBL] [Abstract][Full Text] [Related]
17. Disease activity, damage and survival in Mexican patients with acute severe systemic lupus erythematosus. Zonana-Nacach A; Yañez P; Jiménez-Balderas FJ; Camargo-Coronel A Lupus; 2007; 16(12):997-1000. PubMed ID: 18042596 [TBL] [Abstract][Full Text] [Related]
18. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Nikpour M; Urowitz MB; Ibañez D; Gladman DD Arthritis Rheum; 2009 Sep; 61(9):1152-8. PubMed ID: 19714602 [TBL] [Abstract][Full Text] [Related]